Comment on "Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity".
Er
Hamid
H
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D018450:Disease Progression; D006801:Humans; D007231:Infant, Newborn; D053685:Laser Therapy; D056687:Off-Label Use; D012178:Retinopathy of Prematurity / Q000188:drug therapy*; D016879:Salvage Therapy; D017211:Treatment Failure
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab